Menicon Co., Ltd. (MNNLF)
OTCMKTS · Delayed Price · Currency is USD
7.10
0.00 (0.00%)
Oct 2, 2025, 9:30 AM EDT
Menicon Revenue
Menicon had revenue of 30.25B JPY in the quarter ending June 30, 2025, with 0.32% growth. This brings the company's revenue in the last twelve months to 121.59B, up 3.13% year-over-year. In the fiscal year ending March 31, 2025, Menicon had annual revenue of 121.49B with 4.56% growth.
Revenue (ttm)
121.59B JPY
Revenue Growth
+3.13%
P/S Ratio
0.67
Revenue / Employee
28.11M JPY
Employees
4,325
Market Cap
566.79M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 121.49B | 5.30B | 4.56% |
Mar 31, 2024 | 116.19B | 6.00B | 5.44% |
Mar 31, 2023 | 110.19B | 10.02B | 10.00% |
Mar 31, 2022 | 100.17B | 13.96B | 16.20% |
Mar 31, 2021 | 86.21B | 1.69B | 2.00% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |